STARLIGHT: Patient-Reported Outcomes from a Menopause Symptom Treatment Trial in Japan

147 perimenopausal and postmenopausal women aged 40–65 years from 36 centers in Japan were randomized to receive fezolinetant or placebo for 12 weeks. The dataset contains exploratory patient-reported outcomes (PROs) measuring sleep disturbance, menopause-specific quality of life, and symptom change. Author Kiyoshi Takamatsu published the data under a CC-BY-4.0 license on figshare.

Use Cases

• Analyze the impact of fezolinetant on sleep quality based on PROMIS SD-SF 8b scores mentioned in the description
• Compare menopause-specific quality of life changes across treatment and placebo groups based on MENQOL domain scores
• Evaluate patient-perceived improvement in vasomotor symptoms over time based on PGI-C VMS assessments
• Study correlations between different patient-reported outcome measures in a clinical trial setting

Strengths

• Data originates from a randomized, placebo-controlled phase II clinical trial with 147 participants
• Includes multiple standardized patient-reported outcome instruments (PROMIS, MENQOL, PGI-C) collected at weeks 4, 8, and 12
• Study population is clearly defined: women aged 40–65 from 36 centers in Japan with vasomotor symptoms

Limitations

• Column-level documentation is absent; field semantics must be inferred after download
• Row count is unknown, which may limit suitability assessment
• The PRO analyses were exploratory and not powered for confirmatory hypothesis testing, as noted in the description

Provenance

Source

figshare, author Kiyoshi Takamatsu

Collection Method

Randomized clinical trial (STARLIGHT study) with patient-reported outcome questionnaires

Time Range

Clinical trial period (specific dates not provided)

Freshness

Last updated 2026-05-20 11:20:03; freshness should be verified

Geography

Japan (36 centers)